GlassScriptPhysician profile
Kim L Bango
NPI 1235171711
$1,400.60
in general payments reported to CMS, 2019-2025
17 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.78 · 2020: $91.14 · 2021: $164 · 2022: $102 · 2023: $199 · 2024: $358 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $389.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $202.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $137.53 | 2021-2025 | |
| Exact Sciences Corporation | $132.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $128.85 | 2025 | Airsupra |
| Bausch Health US, LLC | $72.88 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $64.88 | 2020-2022 | |
| Becton, Dickinson and Company | $56.25 | 2024 | Venovo, Crosser Iq |
| Idorsia Pharmaceuticals US INC | $43.53 | 2023-2024 | Quviviq |
| Eisai INC. | $32.53 | 2025 | |
| Abbvie INC. | $22.49 | 2024 | |
| Sanofi Pasteur INC. | $22.22 | 2023 | |
| Phadia US INC. | $21.11 | 2024 | Immunocap |
| Bard Peripheral Vascular, INC. | $19.23 | 2024 | Crosser Iq |
| Astellas Pharma US INC | $19.11 | 2024 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.35 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Bango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.